Physician profile
Brian E Drobny
NPI 1316953136
$5,469.39
in general payments reported to CMS, 2019-2025
11 companies · $575 in 2025
The $575 reported for 2025 was more than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $640 · 2021: $1,124 · 2022: $834 · 2023: $870 · 2024: $459 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,720.29 | 2019-2025 | Total30, Precision7, Precision 7 |
| Johnson & Johnson Vision Care, INC. | $1,645.66 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $951.59 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $602.41 | 2022-2025 | Infuse |
| Rxsight INC | $146.06 | 2023 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| New World Medical,INC. | $138.81 | 2023 | |
| Glaukos Corporation | $114.47 | 2021 | |
| Ocular Therapeutix, INC. | $97.62 | 2021 | |
| Astellas Pharma US INC | $25.21 | 2025 | Izervay |
| Abbvie INC. | $14.11 | 2022 | |
| Eyevance Pharmaceuticals LLC | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Drobny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.